Recently, even patients who have undergone immunotherapy were shown to acquire resistance to PD-1 blockade in melanoma.141 Zaretsky et al. reported a delayed relapse of patients who had had initial tumor regression induced by continuous pembrolizumab treatment. This evidence concerns the gene PDCD1 and neoplasm.